18-Methylaminocoronaridine

From Wikipedia, the free encyclopedia
18-Methylaminocoronaridine
18-MAC structure.png
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H29N3O2
Molar mass367.493 g·mol−1
3D model (JSmol)
  • c4cccc1c4[nH]c3c1CCN2CC(C5)CC3(C(=O)OC)C2C5CCNC
  • InChI=1S/C22H29N3O2/c1-23-9-7-15-11-14-12-22(21(26)27-2)19-17(8-10-25(13-14)20(15)22)16-5-3-4-6-18(16)24-19/h3-6,14-15,20,23-24H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1 checkY
  • Key:YKMOJVPLIUXEIP-SVBQBFEESA-N checkY
  

(–)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist from the Albany Medical College and the chemist from the University of Vermont.[1][2]

See also[]

References[]

  1. ^ Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry. 46 (13): 2716–30. doi:10.1021/jm020562o. PMID 12801235.
  2. ^ Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.
Retrieved from ""